biotech / news / / The Manila Times
Immatics N.V. is the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.
Immatics will present four oral abstracts at the 2026 ASCO Annual Meeting, all selected for talks.
KEY POINTS
- Phase 1b data on anzu-cel in advanced melanoma focuses on characterizing patient-level response dynamics.
- IMA203CD8 showed updated dose-escalation and dose-expansion results in gynecologic cancers at clinically relevant levels.
- Updated Phase 1 data reveals PRAME cell therapies' potential to treat synovial sarcoma beyond melanoma.
- First-in-human results for the MAGEA4/8 bispecific IMA401 suggest combination potential with PRAME bispecific IMA402.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →